ArticleGastro hep advances2026
Association of Cirrhosis Etiology With Outcomes after Transjugular Intrahepatic Portosystemic Shunt: A National Cohort Study.
Article in Gastro hep advances, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Navigating TIPS in the era of ageing and metabolic comorbidity: a contemporary narrative review of risk, resilience, and outcomes.Gastroenterology report · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background and Aims: It is unknown whether outcomes after transjugular intrahepatic portosystemic shunt (TIPS) differ across cirrhosis etiologies, particularly metabolic dysfunction-associated steatotic liver disease (MASLD). We aimed to (i) characterize outcomes by cirrhosis etiology at 90 days and 1 year post-TIPS and (ii) identify features associated with post-TIPS outcomes. Methods: Using a national health system database between 2008 and 2023, we identified adults with cirrhosis who underwent TIPS and performed cumulative incidence function and multivariable competing risk analysis by cirrhosis etiology with primary outcome of mortality and competing risk of transplant. Results: In total, 2846 patients with cirrhosis underwent TIPS (median age 63[interquartile range 56-71], 61% male, 74% non-Hispanic White). Probability of unadjusted transplant-free survival post-TIPS was 84.3% (95% confidence interval [CI] 80.3-88.3) at 90 days and 72.1% (95% CI 67.2-77.0) at 1 year with MASLD, versus alcohol (78.5% [95% CI 76.7-80.3] at 90 days, 68.7% [95% CI 66.7-70.8] at 1 year), viral (78.5% [95% CI 75.6-81.4] at 90 days, 69.1% [95% CI 62.8-75.5] at 1 year), and other etiologies (76.4% [95% CI 73.5-79.4] at 90 days, 62.7% [95% CI 57.7-67.8] at 1 year). In multivariable competing risk regression, MASLD (vs alcohol) was associated with decreased mortality at 90 days (subdistribution hazard ratio 0.59 [95% CI 0.42-0.83]) and 1 year (subdistribution hazard ratio 0.76 [95% CI 0.60, 0.97]) post-TIPS, and similar to viral and other etiologies. Younger age and more recent TIPS were associated with improved survival, whereas pre-TIPS ascites, hepatic encephalopathy, and increasing Charlson Comorbidity Index were associated with increased mortality at 90 days and 1 year post-TIPS. Conclusion: MASLD cirrhosis has excellent short- and long-term survival post-TIPS. Etiology, age, decompensation profile, and comorbidity meaningfully inform risk and should guide counseling and pre- and post-TIPS care.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.